3-Methoxy-4-hydroxyphenylglycol in cerebrospinal fluid and vanillylmandelic acid in urine of humans with hypertension. 1978

R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor

3-Methoxy-4-hydroxyphenylglycol (MHPG) was measured in lumbar spinal fluid of 20 subjects with hypertension of varied etiology and severity. There was a significant correlation between the concentration of MHPG and the severity of hypertension. However, changes in the concentration of vanillylmandelic acid in the urine of these subjects were insignificant. In six subjects, administration of clonidine or alpha-methyldopa, two centrally acting antihypertensive drugs, was associated with a significant lowering of MHPG concentrations. These data support the hypothesis that central catecholamines are involved in clinical hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008734 Methoxyhydroxyphenylglycol Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover. Hydroxymethoxyphenylglycol,MHPG,MOPEG,Vanylglycol,4-Hydroxy-3-methoxyphenylethylene Glycol,4-Hydroxy-3-methoxyphenylethyleneglycol,4-Hydroxy-3-methoxyphenylglycol,Methoxyhydroxyphenylglycol, (+)-Isomer,Methoxyhydroxyphenylglycol, (+-)-Isomer,Methoxyhydroxyphenylglycol, (-)-Isomer,4 Hydroxy 3 methoxyphenylethylene Glycol,4 Hydroxy 3 methoxyphenylethyleneglycol,4 Hydroxy 3 methoxyphenylglycol
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D005260 Female Females
D006018 Glycols A generic grouping for dihydric alcohols with the hydroxy groups (-OH) located on different carbon atoms. They are viscous liquids with high boiling points for their molecular weights.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014642 Vanilmandelic Acid A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE. Methoxyhydroxymandelic Acid,4-Hydroxy-3-Methoxymandelic Acid,Vanillylmandelic Acid,4 Hydroxy 3 Methoxymandelic Acid,Acid, 4-Hydroxy-3-Methoxymandelic,Acid, Methoxyhydroxymandelic,Acid, Vanillylmandelic,Acid, Vanilmandelic

Related Publications

R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
October 1982, Clinica chimica acta; international journal of clinical chemistry,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
September 1968, Biochemical pharmacology,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
August 1976, Neurology,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
July 1976, Journal of neurochemistry,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
January 1983, Science (New York, N.Y.),
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
May 1973, Brain research,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
May 1967, Nihon Sanka Fujinka Gakkai zasshi,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
January 1964, Scripta medica,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
December 1991, Stroke,
R K Saran, and R C Sahuja, and N N Gupta, and M Hasan, and K P Bhargava, and K Shanker, and K Kishor
November 1985, Archives of general psychiatry,
Copied contents to your clipboard!